Using a real-time quantitative PCR assay, we identified two patients with EBV-related lymphoproliferative disorders at a very early stage. Both had received an unmanipulated bone marrow transplant with antithymocyte globulin for conditioning. To estimate virusspecific immunity, the frequencies of EBV-specific CD8 + T cells were measured using an enzyme-linked immunospot assay. The frequencies of EBV-specific CD8 + T cells of the two were 3.2 and 7.7%, respectively, which had possibly expanded in vivo. After withdrawing the immunosuppressive agents or administering donor lymphocytes transfusion, their symptoms regressed in parallel with the viral load. Bone Marrow Transplantation (2000) 26, 199-201. Keywords: EBV; lymphoproliferative disorders; viral load; specific immunity Lymphoproliferative disorders (LPD) are a serious complication of BMT. After a LPD develops, it usually progresses rapidly, and its prognosis is poor.
Lymphoproliferative disorders (LPD) are a serious complication of BMT. After a LPD develops, it usually progresses rapidly, and its prognosis is poor. 1 Several methods have been developed to diagnose LPD using patients' peripheral blood. However, more rapid and sensitive methods are necessary to detect LPD at a very early stage. Recently, we established a rapid system to quantify EBV-DNA using a real-time PCR method, and found that more than 10 2.5 copies of EBV-DNA/g DNA were diagnostic for symptomatic EBV-related lymphoproliferative disorders. 2 Using this system, we were able to diagnose two patients with EBV-related lymphoproliferative disorders at a very early stage. Moreover, to evaluate virus-specific immunity, the frequencies of EBV-specific CD8 + T cells were measured in the two patients.
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Methods
Peripheral blood mononuclear cells (PBMNCs) were obtained from EDTA-treated whole blood. Using a QIAamp DNA Blood Kit (QIAGEN, Hilden, Germany), DNA was extracted from PBMNCs, and 150-200 ng of DNA was used for PCR. The real-time PCR assay was performed as previously described through a Model 7700 Sequence Detector (PE Applied Biosystems, Foster City, CA, USA). 2 The copy number of each sample was calculated automatically by Sequence Detector v1.6 (PE Applied Biosystems) and was expressed per g DNA.
The enzyme-linked immunospot (ELISPOT) assay was performed as previously described with slight modifications. 3 Briefly, a 96-well, MultiScreen-HA plate with a nitrocellulose base (Millipore, Medford, MA, USA) was coated with anti-IFN-␥ mAb (Genzyme, Cambridge, MA, USA). Autologous lymphoblastoid cell lines (LCLs) were prepared from each patient by transforming PBMNCs. CD8 + T cells were isolated from PBMNCs by positive selection with the use of immunomagnetic beads (Dynal, Oslo, Norway). Autologous irradiated LCLs (1 × 10 5 /well) and isolated CD8 + cells were seeded in each well in a graded series. The plate was incubated for 28 h, washed, and reacted with polyclonal rabbit anti-IFN-␥ (Genzyme). The plate was then incubated with peroxidase-conjugated goat anti-rabbit IgG (Genzyme), washed and reacted with 3-amino-9-ethylcarbasole (Sigma, St Louis, MO, USA) for visualization. The plate was washed, dried, and diffuse large spots were counted as antigen-specific CD8 + T cells. Informed consent of the two patients was obtained.
Case reports

Patient 1
Patient 1 was a 10-year-old girl with severe aplastic anemia. She did not respond to combined immunosuppressive therapy with anti-lymphocyte globulin and cyclosporin A (CyA). She received an unmanipulated bone marrow transplant from HLA serologically matched unrelated donor. The preparative regimen included cyclophosphamide (60 mg/kg/day ×2), anti-thymocyte globulin (ATG; Thymoglobulin, Pasteur Merieux, Lyon, France, 2.5 mg/kg/day ×4) and total body irradiation (TBI, 10 Gy) in four divided fractions. Graft-versus-host disease prophylaxis was CyA and short-term methotrexate. She achieved hematological engraftment 17 days later, and no GVHD developed. She became febrile and positive for cytomegalovirus antigenemia in the second week after BMT. Ganciclovir (10 mg/kg/day in divided doses) was administered from day 28 to 51, and the CMV antigen disappeared from peripheral blood. However, she remained pyrexial. Repeated blood cultures were negative for bacterial and fungal growth. We changed the immunosuppressive drugs on day 56 as an empiric treatment for drug allergy. Since her symptoms persisted, we quantified EBV-DNA in her peripheral blood. On day 64, an extremely high number (10 5 .0 copies/g DNA) of EBV genomes were detected in her PBMNCs (Figure 1a) . Total body CT scans disclosed enlarged lymph nodes in the hilum of the left kidney. A biopsy was not performed because of access difficulty. The tacrolimus was stopped immediately and her methylprednisolone was tapered off. She gradually became afebrile, and the EB viral load decreased in parallel with her clinical symptoms. One month later, her peripheral blood became negative for EBV-DNA, although this subsequently reappeared at the level of healthy seropositive donors. The enlarged lymph nodes had disappeared on the CT examination performed 11 days after first examination.
Retrospectively, we measured the frequency of EBVspecific CD8
+ T cells in cryopreserved samples using the ELISPOT assay. The frequency of EBV-specific CD8 + T cells was 3.2% on day 67, a few days after discontinuing tacrolimus (Figure 1a) . Thereafter, the frequency declined in parallel with the EB viral load and clinical symptoms.
Patient 2
Patient 2 was a 20-year-old girl with severe aplastic anemia. Five years before, she had received combined immunosuppressive therapy with anti-lymphocyte globulin and CyA. She responded to the therapy and was in remission. A few years later her disease progressed again. She received an unmanipulated bone marrow transplant from an HLA serologically matched unrelated donor. The preparative regimen and GVHD prophylaxis were the same as those of patient 1. She achieved hematological engraftment 18 days later, and no GVHD developed. Our experiences with patient 1 prompted us to measure the viral load prospectively. We quantified EBV-DNA in the PBMNCs of this patient on day 32, although she did not have any symptoms. Unexpectedly, she had an extremely high EBV genome load (10 4 .0 copies/g DNA) despite appearing completely well (Figure 1b) . Five days later, she developed a fever as high as 39°C, and a cough. The EB viral load increased 32-fold within a few days (10 5.5 copies/g DNA). We had decreased her CyA from 150 to 75 mg/day p.o. immediately after she developed a fever. No anti-viral agent was used. A left mandibular lymph node became palpable and was biopsied. The pathological diagnosis was compatible with LPD. On day 57, a donor lymphocyte transfusion (DLT) consisting of 5 × 10 7 CD3 cells was carried out (indicated by the arrow in Figure 1b) . After DLT, her general condition improved gradually. She became afebrile and the cervical lymphadenopathy regressed. One month later, her symptoms had virtually disappeared. The EB viral load decreased in parallel with her clinical symptoms.
We retrospectively measured the frequency of EBV-specific CD8
+ T cells in her peripheral blood. On day 54 just before the DLT, 7.7% of her CD8 + T cells were EBV-specific (Figure 1b) . We initially thought that the patient had recovered because of the DLT since her symptoms improved after receiving DLT. However, the % EBV-specific CD8 + T cells was highest before DLT. No increase was observed after the administration of DLT. This can be interpreted as the EBV-specific CD8 + T cells expanding endogenously. Since the ELISPOT assay is based on the secretion of IFN-␥, but not on cytotoxicity, a cytotoxic assay was performed by the standard 4 h 51 Cr releasing method. PBMNCs on day 100 post BMT were stimulated with autologous LCLs for 7 days and used as effectors.
They had higher cytotoxicity against autologous LCLs than against HLA-incompatbile LCLs, showing HLA restriction (data not shown).
Discussion
Although the natural course of post-transplant LPD is not fully known, its prognosis is usually poor, unless appropriate treatment is given. 1 It has been shown that DLT is effective for treating LPD. However, the donor lymphocytes also include alloreactive lymphocytes and cause GVHD. In fact, some LPD patients who received DLT died from GVHD. 4, 5 Rooney et al 6 reported a sophisticated adoptive immunotherapy for EBV, and there are some reports on the spontaneous regression of LPD or reconstitution of EBV specific immunity. [7] [8] [9] These reports indicate that endogenous immune reconstitution can be achieved without DLT or adaptively transferred T cells in certain cases of overt LPD, resulting in regression of the disease.
In patient 1, the kinetics of the EBV load and specific immunity against EBV indicate that restoration of EBVspecific immunity caused regression of LPD. The reduction of immunosuppression may have helped the recovery of EBV-specific immunity. These virus-specific CD8 + T cells declined in parallel with the EB viral load and clinical symptoms, possibly due to activation-induced cell death. The high initial frequency of virus-specific CD8 + T cells and the rapid decrease along with antigens were compatible with our previous findings in patients with infectious mononucleosis. 10 In patient 2, a high frequency of EBVspecific CD8
+ T cells was found in the peripheral blood before DLT. Therefore we speculate that endogenously expanded CD8 + T cells also caused regression of LPD in the patient. However, these EBV-specific CD8 + T cells might not be functional. Since we did not perform the cytotoxic assay before DLT, we cannot exclude the possibility that DLT mediated the therapeutic response. It is possible that CD4 + T cells in the DLT product may have provided crucial help, or that the DLT product contained more functionally active CD8 + T cells than the endogenous ones detected by ELISPOT assay.
In view of the rapid, progressive nature of the disease, early diagnosis is crucial for LPD. This may be achieved by monitoring the EB viral load prospectively. For this purpose, the real-time PCR assay is useful, because of its high reproducibility, wide spectrum of activity, and speed. We present data that indicate that adjusting the dose of immunosuppressive agent based on the EB viral load could control the overgrowth of EBV-infected cells in some patients with LPD. Both of them had unmanipulated BMTs with ATG, which has less effect on immunosuppression than does T cell-depleted BMT. It is uncertain that the Bone Marrow Transplantation virus-specific immunity can be established from manipulated bone marrow such as T cell depletion or CD34-positive selection. To confirm such an intervention which can be effective in other types of BMT requires further study. Currently, we are conducting a prospective study using the real-time PCR assay to clarify how often subclinical or overt LPD occurs in high risk BMT patients, and whether intervention causes regression of LPD.
